Charles River Laboratories International, Inc.
Congress has disclosed 11 buys and 8 sells of CRL (Charles River Laboratories International, Inc.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.
Activity Congressional Activity
Round-trip watch Still on the books
Members who disclosed buying CRL and have not disclosed selling, versus their own entry (the most recent disclosed buy). "Open" means no disclosed sale — never "still holds" — and the % is unrealised, on paper. Not investment advice.
| Member | Entry (last buy) | Entry price | Now | vs entry | Status |
|---|---|---|---|---|---|
| Jefferson Shreve | 2025-05-08 | $141.36 | $359.41 | +154.3% | in profit |
| Julie Johnson | 2025-01-15 | $173.91 | $359.41 | +106.7% | in profit |
Price as of 2026-10-30. Counted open while disclosed buys outnumber disclosed sells; tracks the price, not exact position size (amounts are ranges).
Fundamentals · FY2026 Valuation
Standard valuation multiples from SEC-reported GAAP financials (trailing twelve months), each compared to the median for —. We use reported GAAP, not forward or adjusted earnings, so our figures can sit higher than sites that do — especially for companies with falling profit. Relative context — not a target price or investment advice.
how it's calculated
how it's calculated
how it's calculated
19 trades Recent Congressional Trades
Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.
| Politician | Chamber | Type | Owner | Date | Disclosure lag | Price move in that window | Amount | Score | Source |
|---|---|---|---|---|---|---|---|---|---|
| Rob Bresnahan | House | SELL ◆ insider convergence | Self · JP Morgan Brokerage Account | 2025-05-15 | 0 days | 0.0% | $1K–$15K 0.2% of NW |
28.5 | ↗ filing |
| Jefferson Shreve | House | BUY ◆ insider divergence | Self · CRT - Standard Unit Trust | 2025-05-08 | 7 days | -1.7% | $15K–$50K <0.1% of NW |
84.7 | ↗ filing |
| Rob Bresnahan | House | BUY ◆ insider convergence · strong | Self · JP Morgan Brokerage Account | 2025-04-08 | 0 days | 0.0% | $15K–$50K 0.9% of NW |
88.7 | ↗ filing |
| Julie Johnson | House | BUY ◆ insider convergence · strong | Joint · Merrill Lynch Tax Efficient Core | 2025-01-15 | 23 days | -5.8% | $1K–$15K <0.1% of NW |
62.6 | ↗ filing |
| Lois Frankel | House | SELL ◆ insider convergence · moderate | Self · Morgan Stanley IRA - X142 | 2023-09-08 | 28 days | — | $1K–$15K 0.3% of NW |
40.4 | ↗ filing |
| Lois Frankel | House | BUY ◆ insider divergence | Self · Morgan Stanley IRA - X142 | 2023-04-25 | 24 days | — | $1K–$15K 0.3% of NW |
75.9 | ↗ filing |
| Zoe Lofgren | House | SELL | Spouse · John Marshall Collins Rollover IRA | 2022-08-25 | 19 days | — | $1K–$15K 0.1% of NW |
40.4 | ↗ filing |
| Zoe Lofgren | House | BUY | Spouse | 2021-09-30 | 7 days | — | $1K–$15K 0.1% of NW |
75.9 | ↗ filing |
| Susie Lee | House | SELL | Joint | 2019-10-08 | 23 days | — | $1K–$15K 0.2% of NW |
22.3 | ↗ filing |
| Susie Lee | House | SELL | Joint | 2019-10-07 | 24 days | — | $1K–$15K 0.2% of NW |
40.4 | ↗ filing |
| Susie Lee | House | BUY | Joint | 2019-08-29 | 3 days | — | $1K–$15K 0.2% of NW |
75.9 | ↗ filing |
| Donna Shalala | House | SELL | Self | 2019-06-24 | 6 days | — | $1K–$15K | 75.9 | ↗ filing |
| Lamar Smith | House | SELL | Self | 2018-09-26 | 5 days | — | $1K–$15K | 22.3 | ↗ filing |
| Thomas MacArthur | House | BUY | Joint | 2018-09-19 | 12 days | — | $1K–$15K | 15.7 | ↗ filing |
| Thomas MacArthur | House | BUY | Joint | 2018-09-13 | 18 days | — | $1K–$15K | 22.3 | ↗ filing |
| Thomas MacArthur | House | BUY | Joint | 2018-09-12 | 19 days | — | $1K–$15K | 40.4 | ↗ filing |
| Thomas MacArthur | House | BUY | Joint | 2018-09-11 | 20 days | — | $1K–$15K | 75.9 | ↗ filing |
| Lamar Smith | House | SELL | Self | 2018-07-26 | 11 days | — | $1K–$15K | 40.4 | ↗ filing |
| Lamar Smith | House | BUY | Self | 2018-02-13 | 20 days | — | $1K–$15K | 75.9 | ↗ filing |
Corporate insiders · SEC Form 4 Insider Activity
What the company's own officers and directors did in CRL — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →
Of the congressional trades in CRL, 4 coincided with corporate insiders moving the same way within 60 days, and 2 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.
| Date | Insider | Role | Type | Size | Source |
|---|---|---|---|---|---|
| 2026-10-22 | FOSTER JAMES C | Director | SELL 10b5-1 | $8.4M | ↗ EDGAR |
| 2026-10-21 | Parisotto Shannon M | Other | SELL 10b5-1 | $743K | ↗ EDGAR |
| 2026-10-05 | Parisotto Shannon M | Other | SELL 10b5-1 | $303K | ↗ EDGAR |
| 2026-09-30 | Coleman Glenn | C-suite | BUY | $3K | ↗ EDGAR |
| 2026-08-25 | FOSTER JAMES C | Director | SELL 10b5-1 | $10.1M | ↗ EDGAR |
| 2026-08-19 | Parisotto Shannon M | Other | SELL 10b5-1 | $600K | ↗ EDGAR |
| 2026-08-18 | Andrews Nancy C | Director | SELL | $163K | ↗ EDGAR |
| 2026-08-11 | Parisotto Shannon M | Other | SELL 10b5-1 | $1.0M | ↗ EDGAR |
| 2026-08-11 | Girshick Birgit | C-suite | SELL 10b5-1 | $1.8M | ↗ EDGAR |
| 2026-08-10 | FOSTER JAMES C | Director | SELL 10b5-1 | $7.9M | ↗ EDGAR |
| 2026-08-06 | Creamer Victoria L | C-suite | SELL | $1.1M | ↗ EDGAR |
| 2026-08-06 | Knell Michael Gunnar | Other | SELL | $330K | ↗ EDGAR |
| 2026-08-06 | Knell Michael Gunnar | Other | SELL | $235K | ↗ EDGAR |
| 2026-08-06 | Knell Michael Gunnar | Other | SELL | $212K | ↗ EDGAR |
| 2026-08-06 | Knell Michael Gunnar | Other | SELL | $56K | ↗ EDGAR |
| 2026-08-06 | Knell Michael Gunnar | Other | SELL | $164K | ↗ EDGAR |
| 2026-08-06 | Knell Michael Gunnar | Other | SELL | $128K | ↗ EDGAR |
| 2026-08-06 | Knell Michael Gunnar | Other | SELL | $104K | ↗ EDGAR |
| 2026-08-06 | Knell Michael Gunnar | Other | SELL | $312K | ↗ EDGAR |
| 2026-08-06 | Knell Michael Gunnar | Other | SELL | $190K | ↗ EDGAR |
| 2026-08-05 | Parisotto Shannon M | Other | SELL 10b5-1 | $1.3M | ↗ EDGAR |
| 2026-06-29 | FOSTER JAMES C | Director | SELL 10b5-1 | $16.9M | ↗ EDGAR |
| 2026-03-03 | LaPlume Joseph W | Other | BUY | $4K | ↗ EDGAR |
| 2025-08-22 | LaPlume Joseph W | Other | SELL | $65K | ↗ EDGAR |
| 2025-08-18 | LaPlume Joseph W | Other | SELL | $126K | ↗ EDGAR |
Combined timeline — Congress & insiders
Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.
| Date | Who | Type | Size | |
|---|---|---|---|---|
| ◆ insider | 2026-10-22 | FOSTER JAMES C Director 10b5-1 | SELL | $8.4M |
| ◆ insider | 2026-10-21 | Parisotto Shannon M Other 10b5-1 | SELL | $743K |
| ◆ insider | 2026-10-05 | Parisotto Shannon M Other 10b5-1 | SELL | $303K |
| ◆ insider | 2026-09-30 | Coleman Glenn C-suite | BUY | $3K |
| ◆ insider | 2026-08-25 | FOSTER JAMES C Director 10b5-1 | SELL | $10.1M |
| ◆ insider | 2026-08-19 | Parisotto Shannon M Other 10b5-1 | SELL | $600K |
| ◆ insider | 2026-08-18 | Andrews Nancy C Director | SELL | $163K |
| ◆ insider | 2026-08-11 | Parisotto Shannon M Other 10b5-1 | SELL | $1.0M |
| ◆ insider | 2026-08-11 | Girshick Birgit C-suite 10b5-1 | SELL | $1.8M |
| ◆ insider | 2026-08-10 | FOSTER JAMES C Director 10b5-1 | SELL | $7.9M |
| ◆ insider | 2026-08-06 | Creamer Victoria L C-suite | SELL | $1.1M |
| ◆ insider | 2026-08-06 | Knell Michael Gunnar Other | SELL | $330K |
| ◆ insider | 2026-08-06 | Knell Michael Gunnar Other | SELL | $235K |
| ◆ insider | 2026-08-06 | Knell Michael Gunnar Other | SELL | $212K |
| ◆ insider | 2026-08-06 | Knell Michael Gunnar Other | SELL | $56K |
| ◆ insider | 2026-08-06 | Knell Michael Gunnar Other | SELL | $164K |
| ◆ insider | 2026-08-06 | Knell Michael Gunnar Other | SELL | $128K |
| ◆ insider | 2026-08-06 | Knell Michael Gunnar Other | SELL | $104K |
| ◆ insider | 2026-08-06 | Knell Michael Gunnar Other | SELL | $312K |
| ◆ insider | 2026-08-06 | Knell Michael Gunnar Other | SELL | $190K |
| ◆ insider | 2026-08-05 | Parisotto Shannon M Other 10b5-1 | SELL | $1.3M |
| ◆ insider | 2026-06-29 | FOSTER JAMES C Director 10b5-1 | SELL | $16.9M |
| ◆ insider | 2026-03-03 | LaPlume Joseph W Other | BUY | $4K |
| ◆ insider | 2025-08-22 | LaPlume Joseph W Other | SELL | $65K |
FAQ Common questions
How much has Congress traded CRL?
11 disclosed buys and 8 sells of CRL (Charles River Laboratories International, Inc.) appear in official congressional financial disclosures.
Is it legal for members of Congress to trade CRL?
Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.
Where does this data come from?
Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.